This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutEfficacy & SafetyEfficacy &
Safety
Once-Weekly ProphylaxisOn-Demand Bleed ControlSurgical Efficacy
DosingSupport & ResourcesSupport & ResourcesEventsMaterialsVideosResources for Patients and CaregiversAdditional Resources
Related: See information on our hemophilia A productPrescribing Information Indication
Experience MattersBeneFIX Coagulation Factor IX (Recombinant): For once-weekly prophylaxis and on-demand use2BeneFIX: Once-weekly prophylactic and on-demand dosing to fit patients’ lifestyles—from the only recombinant factor IX (FIX) supporting individuals with hemophilia B for more than 20 years.1,2,*
See once-weekly prophylaxis data
Loading
Proven bleed control

A breadth of clinical experience—efficacy and safety studied in previously untreated patients (PUPs) and in previously treated patients (PTPs).2

See on-demand data
Loading
Dosing options to meet patients’ needs

Routine prophylaxis recommended regimen is 100 IU/kg once weekly, and a wide range of vial sizes is available for on-demand bleed control.2

Learn more about dosing options
Loading
Experience matters

Learn about the clinical history and manufacturing and purification process of BeneFIX.

Read more Loading
Access Available in hundreds of institutions nationwide399% of commercially insured patients have access to BeneFIX3
See resources and support options
Loading
Financial assistance

Pfizer has a number of financial support resources and programs for your eligible patients.

Learn more  Loading
Stay connected with BeneFIX and Pfizer

Sign up to receive important information about BeneFIX, hemophilia B, and more.

Register now Loading
References:Center for Biologics Evaluation and Research, US Food and Drug Administration, US Department of Health and Human Services. CBER Approval Letter, Coagulation Factor IX (Recombinant), Genetics Institute, Inc. February 11, 1997. Accessed October 7, 2022. wayback.archive-it.org/7993/20170723024338/https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm057039.htmBeneFIX. Prescribing information. Pfizer Inc.; 2021.Data on file. Pfizer Inc., New York, NY.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2022 Pfizer Inc. All rights reserved.

PP-BEN-USA-0773
You are now leaving PfizerPro You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-BEN-USA-0760
Indication BeneFIX, Coagulation Factor IX (Recombinant), is a human blood coagulation factor indicated in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.  Limitation of use: BeneFIX is not indicated for induction of immune tolerance in patients with hemophilia B. Please see full Prescribing Information for BeneFIX.
Important Safety Information
  • BeneFIX is contraindicated in patients who have manifested life-threatening, immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster protein (CHO).
  • Hypersensitivity reactions, including anaphylaxis, have been reported with BeneFIX. Closely monitor patients for signs and symptoms of acute anaphylaxis, particularly during the early phases of initial exposure to the product. Immediately discontinue the administration of the product and initiate appropriate treatment if symptoms occur.
  • Patients may develop hypersensitivity to hamster protein as BeneFIX contains trace amounts.
  • BeneFIX has been associated with the development of thromboembolic complications, including in patients receiving continuous infusion through a central venous catheter. The safety and efficacy of BeneFIX administration by continuous infusion have not been established.
  • Neutralizing antibodies (inhibitors) have been reported following the administration of BeneFIX. If expected plasma factor IX activity levels are not attained, or if the patient presents with an allergic reaction, or if bleeding is not controlled following an expected dose of BeneFIX, perform an assay that measures factor IX inhibitor concentration.
  • The most common adverse reactions (>5%) from clinical trials were fever, cough, nausea, injection site reaction, injection site pain, headache, dizziness, and rash.
Indication BeneFIX, Coagulation Factor IX (Recombinant), is a human blood coagulation factor indicated in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.Limitation of use:BeneFIX is not indicated for induction of immune tolerance in patients with hemophilia B.Please see full Prescribing Information for BeneFIX.